eligibility_summary
Inclusion: MS diagnosis, RMS or PPMS per 2017 McDonald, first-time subcutaneous ocrelizumab per label. Exclusion: participation in interventional DMT trials, prior or simultaneous same-site participation in CONFIDENCE or MoOzaRt NIS, prior rituximab or ublituximab, severe psychiatric disability, pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/intervention: Ocrelizumab (Ocrevus) given subcutaneously, type: humanized anti‑CD20 IgG1 monoclonal antibody (B‑cell–depleting immunotherapy). Mechanism: binds CD20 on pre‑B and mature B lymphocytes, triggering ADCC, complement‑dependent cytotoxicity, and apoptosis, reduces B‑cell antigen presentation, costimulation, and pro‑inflammatory cytokines, spares stem cells and plasma cells. Targets: CD20+ B cells (especially memory B cells), indirectly dampens T‑cell activation and CNS inflammation. Pathways/biomarkers: B‑cell–driven inflammatory pathway in MS and downstream neuroaxonal injury, assessed via neurofilament light chain (NfL). Study: observational follow‑up of first‑time SC ocrelizumab users, evaluating patient satisfaction (TASQ‑SC) and NfL over 12 months.